Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

A Phase 3 Study to Evaluate Marqibo® in the Treatment of Subjects = 60 Years Old With Newly Diagnosed ALL

Study:

Phase 3 Study of Study to Evaluate Marqibo® in the Combination Chemotherapy in the Treatment of Subjects >or=60 Years Old With Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

Rationale:

n/a

Purpose:

A phase 3 study in the treatment of subjects >or= 60 years old with newly diagnosed acute lymphoblastic leukemia (ALL).

Study Status: Recruiting

Recruiting:
Anjali Advani, MD

Condition Intervention Phase
Acute Lymphoblastic Leukemia (ALL) Drug: Vincristine Sulfate Liposomes Injection (VSLI)
Drug: Vincristine Sulfate Injection (VSI)
Phase 3

Verified by Spectrum Pharmaceuticals, Inc December, 2013

Sponsored by: Spectrum Pharmaceuticals, Inc
Information provided by: Spectrum Pharmaceuticals, Inc
ClinicalTrials.gov identifier: NCT01439347

Study Type: Interventional

Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic
Cleveland, Ohio 44195
United States

Susan M O`Brien, MD., Principal Investigator

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site